GlassScriptPhysician profile
Gerardo Varallo
NPI 1821044496
$7,645.76
in general payments reported to CMS, 2019-2025
37 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $533 · 2021: $1,328 · 2022: $1,111 · 2023: $1,604 · 2024: $1,571 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201 · Education: $41.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.38 |
| Education | $41.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $937.63 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $778.74 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $753.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.83 | 2019-2024 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $450.41 | 2021-2025 | Jesduvroq, Benlysta, Arexvy |
| Bard Peripheral Vascular, INC. | $387.00 | 2020-2024 | Covera |
| Akebia Therapeutics INC | $372.85 | 2019-2025 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $367.49 | 2022-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $353.72 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.14 | 2023-2025 | Jardiance |
| Amgen INC. | $255.23 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $214.88 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $198.65 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $194.12 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $189.84 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $169.42 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $153.69 | 2019-2025 | |
| Baxter Healthcare | $149.42 | 2023 | |
| Mallinckrodt Hospital Products INC. | $128.93 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $127.48 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $102.50 | 2020-2022 | |
| Novo Nordisk INC | $98.42 | 2024-2025 | Rivfloza, Wegovy |
| Daiichi Sankyo INC. | $82.27 | 2020-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $76.22 | 2022-2023 | Gattex |
| Nevro Corp. | $49.63 | 2023 | Senza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.11 | 2021-2024 | |
| Shield Therapeutics INC | $44.27 | 2024 | |
| Nxstage Medical, INC. | $38.08 | 2024 | |
| Apellis Pharmaceuticals, INC. | $21.93 | 2025 | Empaveli |
| Biomerieux INC | $20.50 | 2023 | |
| Lilly USA, LLC | $16.57 | 2024 | Jardiance |
| Arbor Pharmaceuticals, INC. | $16.42 | 2020 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.65 | 2021 | |
| Amicus Therapeutics, INC. | $12.90 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Varallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.